Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 24 01 2019
accepted: 10 04 2019
entrez: 4 6 2019
pubmed: 4 6 2019
medline: 10 9 2020
Statut: epublish

Résumé

BCG is currently the only licensed vaccine against tuberculosis (TB) and confers protection against meningitis and miliary tuberculosis in infants, although pulmonary disease protection in adults is inconsistent. Recently, promising HIV-1 immunogens were developed, such as the T-cell immunogens "tHIVconsvX," designed using functionally conserved protein regions across group M strains, with mosaic immunogens to improve HIV-1 variant match and response breadth. In this study, we constructed an integrative

Identifiants

pubmed: 31156614
doi: 10.3389/fimmu.2019.00923
pmc: PMC6530512
doi:

Substances chimiques

AIDS Vaccines 0
Antigens, Viral 0
BCG Vaccine 0
Vaccines, Live, Unattenuated 0
Vaccines, Synthetic 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

923

Subventions

Organisme : Medical Research Council
ID : G1001757
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N023668/1
Pays : United Kingdom

Références

Science. 1999 Jul 30;285(5428):732-6
pubmed: 10426995
J Bacteriol. 1999 Aug;181(16):4780-9
pubmed: 10438745
Nat Med. 2000 Sep;6(9):951-5
pubmed: 10973301
Vaccine. 2001 Feb 28;19(15-16):2146-51
pubmed: 11228387
Wkly Epidemiol Rec. 2004 Jan 23;79(4):27-38
pubmed: 14768305
J Immunol. 2004 Mar 15;172(6):3491-500
pubmed: 15004149
Microbiology. 2005 May;151(Pt 5):1443-52
pubmed: 15870454
Microb Pathog. 2005 Jul-Aug;39(1-2):35-43
pubmed: 15967629
J Virol. 2005 Oct;79(20):12871-9
pubmed: 16188989
J Virol. 2006 Feb;80(4):1645-52
pubmed: 16439521
J Virol. 2006 Mar;80(6):3122-5
pubmed: 16501126
J Virol. 2007 Jan;81(1):74-83
pubmed: 17050608
Expert Rev Vaccines. 2006 Dec;5(6):827-38
pubmed: 17184220
J Virol. 2007 Sep;81(17):9408-18
pubmed: 17596303
PLoS One. 2007 Oct 03;2(10):e984
pubmed: 17912361
J Biotechnol. 2008 Mar 20;134(1-2):127-36
pubmed: 18308411
Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3111-5
pubmed: 1901654
J Clin Invest. 2009 May;119(5):1167-77
pubmed: 19381021
Infect Immun. 2009 Aug;77(8):3364-73
pubmed: 19487476
Vaccine. 2009 Jul 30;27(35):4857-66
pubmed: 19520196
Curr HIV Res. 2010 Jun;8(4):282-98
pubmed: 20353397
J Virol. 2010 Jun;84(12):5898-908
pubmed: 20375158
Nature. 1991 Jun 6;351(6326):479-82
pubmed: 2046750
J Biomed Biotechnol. 2010;2010:357370
pubmed: 20617151
Clin Dev Immunol. 2011;2011:516219
pubmed: 21603216
Tuberc Res Treat. 2011;2011:574591
pubmed: 22567267
PLoS One. 2012;7(8):e42559
pubmed: 22927933
J Infect Dis. 2013 Oct 15;208(8):1231-9
pubmed: 23878319
Mol Ther. 2014 Feb;22(2):464-475
pubmed: 24166483
PLoS One. 2014 Jul 09;9(7):e101591
pubmed: 25007091
Clin Vaccine Immunol. 2014 Oct;21(10):1385-95
pubmed: 25080550
Clin Vaccine Immunol. 2014 Nov;21(11):1565-72
pubmed: 25230940
Infect Immun. 2014 Dec;82(12):5317-26
pubmed: 25287928
Clin Vaccine Immunol. 2015 Jul;22(7):726-41
pubmed: 25924766
Mol Ther Methods Clin Dev. 2014 May 21;1:14017
pubmed: 26015961
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8379-84
pubmed: 26100867
Mol Ther. 2016 Apr;24(4):832-42
pubmed: 26743582
Mol Ther. 2017 Feb 1;25(2):494-503
pubmed: 28153096
Hum Vaccin Immunother. 2017 Aug 3;13(8):1798-1810
pubmed: 28426273
J Int AIDS Soc. 2017 May 19;20(1):21171
pubmed: 28537062
Hum Vaccin Immunother. 2017 Dec 2;13(12):3020-3032
pubmed: 29083948
Vaccine. 2018 Jun 7;36(24):3408-3410
pubmed: 29609965
Expert Rev Vaccines. 2018 Nov;17(11):1005-1020
pubmed: 30300040
Mol Ther Methods Clin Dev. 2018 Oct 26;12:32-46
pubmed: 30547051
Mol Ther Methods Clin Dev. 2019 Feb 07;13:253-264
pubmed: 30859110
Proc Natl Acad Sci U S A. 1988 Mar;85(6):1917-21
pubmed: 3279420
Dev Biol Stand. 1986;58 ( Pt A):191-205
pubmed: 3297863
J Biol Stand. 1988 Jan;16(1):15-26
pubmed: 3350821
J Virol. 1994 Jul;68(7):4650-5
pubmed: 8207839
J Exp Med. 1993 Jul 1;178(1):197-209
pubmed: 8315378
J Immunol. 1998 Sep 15;161(6):2985-93
pubmed: 9743362
J Clin Invest. 1998 Nov 1;102(9):1758-65
pubmed: 9802890
Clin Exp Immunol. 1998 Nov;114(2):196-203
pubmed: 9822276

Auteurs

Athina Kilpeläinen (A)

AIDS Research Unit, Infectious Diseases Department, Catalan Center for HIV Vaccine Research and Development, Hospital Clínic/IDIBAPS, Barcelona, Spain.

Narcís Saubi (N)

AIDS Research Unit, Infectious Diseases Department, Catalan Center for HIV Vaccine Research and Development, Hospital Clínic/IDIBAPS, Barcelona, Spain.

Núria Guitart (N)

AIDS Research Unit, Infectious Diseases Department, Catalan Center for HIV Vaccine Research and Development, Hospital Clínic/IDIBAPS, Barcelona, Spain.

Nathifa Moyo (N)

The Jenner Institute Laboratories, University of Oxford, Oxford, United Kingdom.

Edmund G Wee (EG)

The Jenner Institute Laboratories, University of Oxford, Oxford, United Kingdom.

Krupa Ravi (K)

The Jenner Institute Laboratories, University of Oxford, Oxford, United Kingdom.

Tomáš Hanke (T)

The Jenner Institute Laboratories, University of Oxford, Oxford, United Kingdom.
International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan.

Joan Joseph (J)

AIDS Research Unit, Infectious Diseases Department, Catalan Center for HIV Vaccine Research and Development, Hospital Clínic/IDIBAPS, Barcelona, Spain.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH